These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1710541)

  • 1. Quality of life assessment. An independent prognostic variable for survival in lung cancer.
    Ganz PA; Lee JJ; Siau J
    Cancer; 1991 Jun; 67(12):3131-5. PubMed ID: 1710541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
    Ellis PA; Smith IE; Hardy JR; Nicolson MC; Talbot DC; Ashley SE; Priest K
    Br J Cancer; 1995 Feb; 71(2):366-70. PubMed ID: 7530988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?
    Ganz PA; Figlin RA; Haskell CM; La Soto N; Siau J
    Cancer; 1989 Apr; 63(7):1271-8. PubMed ID: 2465815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
    Kelly K; Crowley J; Bunn PA; Presant CA; Grevstad PK; Moinpour CM; Ramsey SD; Wozniak AJ; Weiss GR; Moore DF; Israel VK; Livingston RB; Gandara DR
    J Clin Oncol; 2001 Jul; 19(13):3210-8. PubMed ID: 11432888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.
    Spiro SG; Rudd RM; Souhami RL; Brown J; Fairlamb DJ; Gower NH; Maslove L; Milroy R; Napp V; Parmar MK; Peake MD; Stephens RJ; Thorpe H; Waller DA; West P;
    Thorax; 2004 Oct; 59(10):828-36. PubMed ID: 15454647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
    Strøm HH; Bremnes RM; Sundstrøm SH; Helbekkmo N; Aasebø U
    Clin Lung Cancer; 2015 May; 16(3):183-92. PubMed ID: 25481662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.
    Smith IE; O'Brien ME; Talbot DC; Nicolson MC; Mansi JL; Hickish TF; Norton A; Ashley S
    J Clin Oncol; 2001 Mar; 19(5):1336-43. PubMed ID: 11230476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
    Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
    Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
    J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.
    Kosty MP; Fleishman SB; Herndon JE; Coughlin K; Kornblith AB; Scalzo A; Morris JC; Mortimer J; Green MR
    J Clin Oncol; 1994 Jun; 12(6):1113-20. PubMed ID: 8201372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
    Richards F; Perry DJ; Goutsou M; Modeas C; Muchmore E; Rege V; Chahinian AP; Hirsh V; Poiesz B; Green MR
    Cancer; 1991 Jun; 67(12):2974-9. PubMed ID: 1646066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.
    Cullen MH; Billingham LJ; Woodroffe CM; Chetiyawardana AD; Gower NH; Joshi R; Ferry DR; Rudd RM; Spiro SG; Cook JE; Trask C; Bessell E; Connolly CK; Tobias J; Souhami RL
    J Clin Oncol; 1999 Oct; 17(10):3188-94. PubMed ID: 10506617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
    Song SY; Kim WS; Kim K; Jung CW; Im YH; Kim HJ; Kang WK; Lee HG; Kwon OJ; Rhee CH; Park CH; Park K
    Jpn J Clin Oncol; 2003 Oct; 33(10):509-13. PubMed ID: 14623918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
    Takifuji N; Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Masuda N; Ryu S; Sakai N; Kubota K
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel/platinum combination provides quality-of-life advantage over vinorelbine/cisplatin in advanced lung cancer.
    Oncology (Williston Park); 2002 Aug; 16(8):1052. PubMed ID: 12201644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.